Literature DB >> 7621511

Inhibition of gene expression with ribozymes.

P Marschall1, J B Thomson, F Eckstein.   

Abstract

1. Ribozymes can be designed to cleave in trans, i.e. several substrate molecules can be turned over by one molecule of the catalytic RNA. Only small molecular weight ribozymes, or small ribozymes, are discussed in this review with particular emphasis on the hammerhead ribozyme as this has been most widely used for the inhibition of gene expression by cleavage of mRNAs. 2. Cellular delivery of the ribozyme is of crucial importance for the success of inhibition of gene expression by this methodology. Two modes of delivery can be envisaged, endogenous and exogenous delivery. Of the former several variants exist, depending on the vector used. The latter is still in its infancy, even though chemical modification has rendered such ribozymes resistant against degradation by serum nucleases without impairment of catalytic efficiency. 3. Various successful applications of ribozymes for the inhibition of gene expression are discussed, with particular emphasis on HIV1 and cancer targets. These examples demonstrate the promise of this methodology.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7621511     DOI: 10.1007/bf02088835

Source DB:  PubMed          Journal:  Cell Mol Neurobiol        ISSN: 0272-4340            Impact factor:   5.046


  73 in total

1.  High-efficiency receptor-mediated delivery of small and large (48 kilobase gene constructs using the endosome-disruption activity of defective or chemically inactivated adenovirus particles.

Authors:  M Cotten; E Wagner; K Zatloukal; S Phillips; D T Curiel; M L Birnstiel
Journal:  Proc Natl Acad Sci U S A       Date:  1992-07-01       Impact factor: 11.205

Review 2.  The in vivo application of ribozymes.

Authors:  M Cotten
Journal:  Trends Biotechnol       Date:  1990-07       Impact factor: 19.536

Review 3.  Ribozymes as anti-HIV-1 therapeutic agents: principles, applications, and problems.

Authors:  J J Rossi; D Elkins; J A Zaia; S Sullivan
Journal:  AIDS Res Hum Retroviruses       Date:  1992-02       Impact factor: 2.205

4.  Ribozymes designed to inhibit transformation of NIH3T3 cells by the activated c-Ha-ras gene.

Authors:  M Koizumi; H Kamiya; E Ohtsuka
Journal:  Gene       Date:  1992-08-15       Impact factor: 3.688

5.  Intracellular distribution of microinjected antisense oligonucleotides.

Authors:  J P Leonetti; N Mechti; G Degols; C Gagnor; B Lebleu
Journal:  Proc Natl Acad Sci U S A       Date:  1991-04-01       Impact factor: 11.205

Review 6.  Self-cleaving catalytic RNA.

Authors:  D M Long; O C Uhlenbeck
Journal:  FASEB J       Date:  1993-01       Impact factor: 5.191

Review 7.  Human gene therapy.

Authors:  R A Morgan; W F Anderson
Journal:  Annu Rev Biochem       Date:  1993       Impact factor: 23.643

8.  Incorporation of the catalytic domain of a hammerhead ribozyme into antisense RNA enhances its inhibitory effect on the replication of human immunodeficiency virus type 1.

Authors:  M Homann; S Tzortzakaki; K Rittner; G Sczakiel; M Tabler
Journal:  Nucleic Acids Res       Date:  1993-06-25       Impact factor: 16.971

9.  Antisense oligonucleotide inhibition of acetylcholinesterase gene expression induces progenitor cell expansion and suppresses hematopoietic apoptosis ex vivo.

Authors:  H Soreq; D Patinkin; E Lev-Lehman; M Grifman; D Ginzberg; F Eckstein; H Zakut
Journal:  Proc Natl Acad Sci U S A       Date:  1994-08-16       Impact factor: 11.205

10.  Kinetics and mechanisms for removal of circulating single-stranded DNA in mice.

Authors:  W Emlen; M Mannik
Journal:  J Exp Med       Date:  1978-03-01       Impact factor: 14.307

View more
  12 in total

1.  Comparison of the specificities and catalytic activities of hammerhead ribozymes and DNA enzymes with respect to the cleavage of BCR-ABL chimeric L6 (b2a2) mRNA.

Authors:  T Kuwabara; M Warashina; T Tanabe; K Tani; S Asano; K Taira
Journal:  Nucleic Acids Res       Date:  1997-08-01       Impact factor: 16.971

2.  A modular and extensible RNA-based gene-regulatory platform for engineering cellular function.

Authors:  Maung Nyan Win; Christina D Smolke
Journal:  Proc Natl Acad Sci U S A       Date:  2007-08-20       Impact factor: 11.205

3.  Selection of the best target site for ribozyme-mediated cleavage within a fusion gene for adenovirus E1A-associated 300 kDa protein (p300) and luciferase.

Authors:  H Kawasaki; J Ohkawa; N Tanishige; K Yoshinari; T Murata; K K Yokoyama; K Taira
Journal:  Nucleic Acids Res       Date:  1996-08-01       Impact factor: 16.971

4.  Specificity of hammerhead ribozyme cleavage.

Authors:  K J Hertel; D Herschlag; O C Uhlenbeck
Journal:  EMBO J       Date:  1996-07-15       Impact factor: 11.598

5.  Characterization of several kinds of dimer minizyme: simultaneous cleavage at two sites in HIV-1 tat mRNA by dimer minizymes.

Authors:  T Kuwabara; S V Amontov; M Warashina; J Ohkawa; K Taira
Journal:  Nucleic Acids Res       Date:  1996-06-15       Impact factor: 16.971

6.  Peptide nucleic acid (PNA) is capable of enhancing hammerhead ribozyme activity with long but not with short RNA substrates.

Authors:  E Jankowsky; G Strunk; B Schwenzer
Journal:  Nucleic Acids Res       Date:  1997-07-15       Impact factor: 16.971

Review 7.  Strategy for designing specific antisense oligonucleotide sequences.

Authors:  M Mitsuhashi
Journal:  J Gastroenterol       Date:  1997-04       Impact factor: 7.527

8.  Ribozyme-mediated RNA degradation in nuclei suspension.

Authors:  O Heidenreich; S H Kang; D A Brown; X Xu; P Swiderski; J J Rossi; F Eckstein; M Nerenberg
Journal:  Nucleic Acids Res       Date:  1995-06-25       Impact factor: 16.971

9.  Comparative analysis of cleavage rates after systematic permutation of the NUX consensus target motif for hammerhead ribozymes.

Authors:  M Zoumadakis; M Tabler
Journal:  Nucleic Acids Res       Date:  1995-04-11       Impact factor: 16.971

10.  Chemically modified ribozyme targeting TNF-alpha mRNA regulates TNF-alpha and IL-6 synthesis in synovial fibroblasts of patients with rheumatoid arthritis.

Authors:  Minako Takahashi; Tadao Funato; Yoko Suzuki; Hiroshi Fujii; Keiko Kumura Ishii; Mitsuo Kaku; Takeshi Sasaki
Journal:  J Clin Immunol       Date:  2002-07       Impact factor: 8.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.